Xilio Therapeutics - Edison Group

Xilio Therapeutics (XLO)

Last close As at 26/10/2026

USD7.31

▲ −0.26 (−3.43%)

Market capitalisation

USD49m

Overview
Thematics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer.

Share Price Chart

Market Data

Share Price USD7.31

Market Cap USD49m

52-Week High USD12.46

52-Week Low USD6.62

% Change 1M (19.2)

% Change 6M (10.6)

% Change 12M (37.1)

Ave. Daily Volume 1yr 6,480

Sector

Healthcare

Equity Analyst

Arron Aatkar, PhD

Analyst

Key Management

René Russo

CEO
Chris Frankenfield

CFO

thematic

Healthcare

18.02.26

Redesigning immunity: The next frontier in immuno-oncology

thematic

Healthcare

11.11.25

Edison explains: Investing in health stocks – how policy clarity is opening doors

thematic

Healthcare

22.09.25

The CNS renaissance: Innovations are reshaping neurological therapies

thematic

Healthcare

11.11.24

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

20.11.23

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

thematic

Healthcare

13.11.23

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways - Edison Group

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

Machine learning in drug development - Edison Group

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

Cancer cells

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

cell DNA double helix

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

IPO apocalypse - Edison Group

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick - Edison Group

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

Healthcare

22.03.21

Seven things every investor should know about SIGA technologies & biological weapons

thematic

Healthcare

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

Healthcare

30.10.19

Edison Exhibits- antibiotic development

thematic

Healthcare

17.07.19

The next wave in AMD

thematic

Healthcare

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

Healthcare

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

Healthcare

04.03.19

Drug pricing – Market access and reimbursement

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

Healthcare

21.06.17

ASCO 2017

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Healthcare

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Healthcare

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Healthcare

28.05.12

Edison healthcare quarterly: How to please some of the people some of the time